Modopar 250 is a prescription antiparkinsonian medicine containing 200 mg of levodopa and 50 mg of benserazide per capsule. It is designed for the symptomatic treatment of Parkinson's disease and related movement disorders associated with dopamine deficiency.
Levodopa is converted into dopamine within the brain, helping improve motor function. Benserazide inhibits the peripheral breakdown of levodopa, increasing the amount reaching the central nervous system while reducing peripheral adverse effects.
Each capsule contains:
Modopar 250 is prescribed for:
Dosage should always be determined by a qualified healthcare professional. Treatment is individualized according to the patient's condition and clinical response.
Possible adverse reactions include:
Patients should seek medical advice if severe side effects occur.
Do not use in patients with:
Store in the original package under the manufacturer's recommended conditions. Keep away from moisture, heat, and children.
It is prescribed for the treatment of Parkinson's disease and related movement disorders.
Each capsule contains 200 mg levodopa and 50 mg benserazide.
No. It is a prescription medication and should only be used under medical supervision.
The onset of action varies depending on the patient and prescribed treatment regimen.
No. Treatment should only be discontinued or adjusted under the supervision of a healthcare professional.
Ask a question or inquire about delivery to your country

